DNAprint Genomics (DNAG)

[johnnyfiber]

Chris, my only agenda is I am a long time shareholder in DNAP/DNAG. I never posted much, but did keep up. I do believe we are on the threshold of what Frudakis outlined many years ago. Whether or not the common shareholders participate remains to be seen.

Advice:
Be very wary of the preferred shares being authorized

Anyway,
Do you recall years ago over on RB, that dnaprint.co/za site being posted and everybody wondering what it was. I just don't remember for certain.

Yes, it's all speculation, but...this isn't: We do have an agreement with Emory. Merck is using Emory. We do know that the vaccine was a joint collaboration b/w Pfizer and Merck. Pfizer has gone to Phase III trials while Merck has gone to Phase IIb to further develop safety and efficacy.

We have the High throughput capabilities b/w Dnaprint and Ellipsis. The question is: Are they going to be incorporating Ancestry to determine populations for testing this vaccine. We don't know. What work has been done on MK-0518 (see below)that could assist in the development of MRKAd5 HIV-1 ?

Why do I think they are going to use us? because they say this in the release: "and whether it would be effective in populations with pre-existing immunity to the viral vector used in the vaccine,

What does that mean?

This article is old and the approach is different but the problem stll exists. It's the same problem with every drug. It needs to be personalized.

Antiretroviral drug combination has been effective in dramatically reducing HIV-related mortality and morbidity. However, nearly half of HIV-infected patients still fail the treatment. Although genetic analyses of viral genomes from these patients show multiple-drug resistance mutations in the pol gene, the molecular mechanisms for the emergence of drug-resistance are not yet known. Therefore, it is important to delineate the mechanisms for multiple-drug resistance in order to more efficiently control HIV infection.

http://www.cbimms.duke.edu/gao.htm

I believe we are to be used, to some extent, as a control mechanism in this study. I also believe we need to advance our technology.

"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics," said Dr. MarkBouzyk, Director of Emory's Center for Medical Genomics.

http://www.bioportfolio.com/august_06/18_08_2006/DNAPrint_Genomics_and_Emory.html

I know our technology is being utilized at Emory since August 17, 2006 and I believe Merck is going to afford us the opportunity to advance that technology.

Notice dates. I DON’T believe in coincidence!! JMHO

SARASOTA, FL, August 17 / MARKET WIRE/ --
DNAPrint Genomics, Inc. (OTCBB: DNAG) todayannounced that it has entered into an agreement that will enable the Center for Medical Genomics, Emory University Department of Human Genetics to utilize the Company's Ancestry Informative Marker


August 17, 2006

Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options
Worldwide Access Program Will Be Conducted Along With Phase III Studies

http://www.thebody.com/press/mk0518_access.html

MK-0518

MK-0518 is the first inhibitor of integrase-the step in HIV’s lifecycle where the HIV genome is inserted into the host’s DNA—to reach phase II/III efficacy trials. Two integrase inhibitors are now in the clinic,
and several preclinical integrase programs are underway in drug discovery programs around the world(see TAG’s preclinical ARV pipeline chart at

www.aidsinfonyc.org/tag/tx/pipeline2006a.html).

http://aidsinfonyc.org/tag/tagline/pipeline2006.pdf

I believe we’re going to be hearing a lot more about the drugs in the above link. We came on board with MK-0518 (which is a more potent drug than MRKAd5 HIV-1) and is now in Phase II/III after showing it was well tolerated with few side effects. . Do we have the technology?

http://www.bioportfolio.com/november_06/03_11_2006/Roche_presents_positive_new.html

2007 FEB 5 - (NewsRx.com) -- An update on recent developments released by Merck.

Levels of total cholesterol and triglycerides were not increased in HIV-infected patients taking MK-0518, an investigational integrase inhibitor being developed by Merck & Co., Inc., with tenofovir (Viread) and lamivudine (Epivir).
In contrast, increased levels of both lipid parameters were observed in patients taking efavirenz (Sustiva) combined with the same drugs.

The interim 24-week results are from an ongoing 48-week study in 198 treatment-naive HIV-infected patients,
MK-0518 belongs to a new class of investigational antiretroviral therapy agents called integrase inhibitors that inhibit the insertion of the HIV viral DNA into human DNA. Inhibiting integrase from performing this essential function blocks the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit the other two enzymes involved in viral replication - protease and reverse transcriptase - but there are no approved drugs that inhibit integrase.

Important data, eh? I’ve read about this new class of drugs being used to stop the spread of cancer. Notice dates…study started when we came in and EAP was made public.

http://209.85.165.104/search?q=cache:0jZijX6DfvQJ:calibre.mworld.com/m/m.w%3Flp%3DGetStory%26id%3D24...

The further we spread the more validity that gets attached to our utility.

One thing. Either way, it sound like we’re in Mercks’ pocket. That means making us solvent. JMHO

Oh Yeah, there’s also M2gen , oh my…

We'll know soon.

For those who believe connecting the dots is futile: Just remember...people are convicted and sent to the gas chamber on circumstantial evidence.

Make of it what you will...GOOD LUCK!!